Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nadine Jackson McCleary, M.D.

Co-Author

This page shows the publications co-authored by Nadine McCleary and Jeffrey Meyerhardt.
Connection Strength

4.539
  1. Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1489-98.
    View in: PubMed
    Score: 0.654
  2. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
    View in: PubMed
    Score: 0.539
  3. In reply. Oncologist. 2013; 18(12):1331.
    View in: PubMed
    Score: 0.539
  4. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013 Mar; 12(1):62-9.
    View in: PubMed
    Score: 0.532
  5. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 2010 Feb 15; 116(4):957-66.
    View in: PubMed
    Score: 0.441
  6. New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient. Oncology (Williston Park). 2010 Jan; 24(1 Suppl 1):3-8.
    View in: PubMed
    Score: 0.437
  7. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009 Jun 15; 115(12):2617-29.
    View in: PubMed
    Score: 0.421
  8. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11).
    View in: PubMed
    Score: 0.233
  9. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2018 01; 9(1):24-31.
    View in: PubMed
    Score: 0.186
  10. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013 Jul 10; 31(20):2600-6.
    View in: PubMed
    Score: 0.139
  11. Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2021 Oct 12.
    View in: PubMed
    Score: 0.062
  12. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379.
    View in: PubMed
    Score: 0.052
  13. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
    View in: PubMed
    Score: 0.052
  14. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.049
  15. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
    View in: PubMed
    Score: 0.037
  16. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
    View in: PubMed
    Score: 0.036
  17. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
    View in: PubMed
    Score: 0.034
  18. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
    View in: PubMed
    Score: 0.034
  19. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012 Jul 20; 30(21):2624-34.
    View in: PubMed
    Score: 0.032
  20. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.